Published in J Clin Oncol on September 08, 2015
The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol (2017) 1.04
Walking the Tightrope Between Treatment Efficacy and Price. J Clin Oncol (2015) 0.79
The cost and value of cancer drugs - are new innovations outpacing our ability to pay? Isr J Health Policy Res (2016) 0.79
[The problem of the cost of new oncologic therapies: what about Morocco?]. Pan Afr Med J (2016) 0.75
An update on clinical oncology for the non-oncologist. Einstein (Sao Paulo) (2016) 0.75
Recent advances in the medical treatment of breast cancer. F1000Res (2016) 0.75
Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist (2016) 0.75
Defining Health Across the Cancer Continuum. Cureus (2017) 0.75
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat (2016) 0.75
The role of Dickkopf family in cancers: from Bench to Bedside. Am J Cancer Res (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2011) 7.10
Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med (2009) 6.46
Survival of Medicare patients after enrollment in hospice programs. N Engl J Med (1996) 6.14
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97
HER-2 testing in breast cancer using parallel tissue-based methods. JAMA (2004) 4.60
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making (1985) 4.47
What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med (2003) 3.88
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 3.87
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer (2004) 3.50
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm (1994) 2.42
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making (2012) 2.21
Extending survival with chemotherapy in metastatic breast cancer. Oncologist (2005) 2.17
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol (2007) 2.09
Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med (2008) 1.95
United States life tables, 2010. Natl Vital Stat Rep (2014) 1.84
Length of survival of patients with cancer in hospice: a retrospective analysis of patients treated at a major cancer center versus other practice settings. J Palliat Med (2007) 1.81
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics (1996) 1.75
Handling uncertainty in economic evaluations of healthcare interventions. BMJ (1999) 1.64
Health care costs for patients with cancer at the end of life. J Oncol Pract (2012) 1.51
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol (2013) 1.08
A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics (1996) 1.02
Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer (2011) 0.96
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist (2012) 0.91
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care (Basel) (2013) 0.90
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus (2014) 0.85
How should we design supportive cancer care? The patient's perspective. J Clin Oncol (2008) 0.82
Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. Pharmacoeconomics (2015) 0.81
Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ (2014) 0.80